Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
92 studies found for:    "Liposarcoma"
Show Display Options
Rank Status Study
21 Active, not recruiting A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
Conditions: Solid Tumors;   Virally Mediated Cancers and Liposarcoma
Intervention: Drug: oral 5-azacitidine in combination with romidepsin
22 Recruiting Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum
Conditions: Retroperitoneal Liposarcoma;   Retroperitoneal Leiomyosarcoma;   Chondrosarcoma
Intervention: Drug: Nilotinib-adriamycin
23 Recruiting SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo
24 Terminated
Has Results
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
Conditions: Adult Liposarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: nelfinavir mesylate;   Procedure: biopsy;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Genetic: gene expression analysis;   Genetic: western blotting;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique
25 Completed
Has Results
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Conditions: Liposarcoma;   Leiomyosarcoma
Interventions: Drug: Yondelis;   Drug: Dexamethasone
26 Completed Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Conditions: Leiomyosarcoma;   Liposarcoma
Intervention: Drug: Gemcitabine + Trabectedin
27 Recruiting Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Conditions: Conventional Chondrosarcoma;   Myxoid Liposarcoma;   Mesenchymal Chondrosarcoma;   Dedifferentiated Chondrosarcoma
Intervention: Drug: sirolimus and cyclophosphamide
28 Active, not recruiting Rosiglitazone in Treating Patients With Liposarcoma
Condition: Sarcoma
Intervention: Drug: rosiglitazone maleate
29 Active, not recruiting Troglitazone in Treating Patients With Liposarcoma
Condition: Sarcoma
Intervention: Drug: troglitazone
30 Completed A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
Condition: Sarcoma
Intervention: Drug: RO5045337
31 Withdrawn NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Conditions: Adult Synovial Sarcoma;   Myxoid/Round Cell Liposarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis
32 Recruiting Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
Conditions: Myxoid Liposarcoma;   Round Cell Liposarcoma;   Synovial Sarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Recombinant Interferon Gamma
33 Recruiting Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Conditions: Liposarcoma, Myxoid;   Sarcoma, Soft Tissue
Interventions: Drug: Trabectedin;   Radiation: Radiotherapy
34 Completed Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Conditions: Adult Liposarcoma;   Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: cyclophosphamide;   Biological: NY-ESO-1-specific T cells;   Other: laboratory biomarker analysis
35 Recruiting Detection of Circulating Tumor Cells in Patients With Sarcomas
Conditions: Leiomyosarcoma;   Pleomorphic Liposarcoma;   Synovial Sarcoma;   Liposarcoma
Intervention:
36 Recruiting Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Conditions: Adult Liposarcoma;   Metastatic Liposarcoma;   Metastatic Osteosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Liposarcoma;   Recurrent Osteosarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: Pazopanib Hydrochloride;   Drug: Oral Topotecan Hydrochloride;   Other: Laboratory Biomarker Analysis
37 Completed
Has Results
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Conditions: Liposarcoma;   Leiomyosarcoma;   Fibrosarcoma;   Malignant Fibrous Histiocytoma
Intervention: Drug: Sunitinib Malate (SU011248)
38 Recruiting Trial of CMB305 and Atezolizumab in Patients With Sarcoma
Conditions: Sarcoma;   Myxoid/Round Cell Liposarcoma;   Synovial Sarcoma;   Metastatic Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Locally Advanced Sarcoma;   Liposarcoma
Interventions: Biological: CMB305;   Biological: atezolizumab
39 Completed Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Conditions: Leiomyosarcoma;   Liposarcoma;   Osteosarcoma;   Sarcoma, Soft Tissue;   Metastases
Intervention: Drug: ridaforolimus
40 Completed An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Conditions: Ovarian Neoplasms;   Colorectal Neoplasms;   Melanoma;   Small Cell Lung Cancer;   Liposarcoma
Interventions: Radiation: Ionizing radiation (IR) therapy;   Radiation: Ionizing radiation (IR)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.